12/5
05:43 am
alny
Do Alnylam Pharmaceuticals' (ALNY) Board Moves Quietly Reframe Its Management Incentives and Risk Profile? [Yahoo! Finance]
Low
Report
Do Alnylam Pharmaceuticals' (ALNY) Board Moves Quietly Reframe Its Management Incentives and Risk Profile? [Yahoo! Finance]
12/3
08:00 am
alny
Alnylam Pharmaceuticals Announces Changes to Board of Directors
Low
Report
Alnylam Pharmaceuticals Announces Changes to Board of Directors
12/1
06:58 am
alny
Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value [Yahoo! Finance]
Low
Report
Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value [Yahoo! Finance]
11/27
07:22 am
alny
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3 [Seeking Alpha]
Low
Report
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3 [Seeking Alpha]
11/24
11:47 pm
alny
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After Recent Share Price Pullback [Yahoo! Finance]
Low
Report
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After Recent Share Price Pullback [Yahoo! Finance]
11/21
11:17 pm
alny
Highflying Biotech Stock Sets Up After 96% Pop; Annual Profit In Sight As Key Drug Sales Double [Yahoo! Finance]
Low
Report
Highflying Biotech Stock Sets Up After 96% Pop; Annual Profit In Sight As Key Drug Sales Double [Yahoo! Finance]
11/20
06:58 pm
alny
Abrdn Life Sciences Investors Q3 2025 Commentary [Seeking Alpha]
Low
Report
Abrdn Life Sciences Investors Q3 2025 Commentary [Seeking Alpha]
11/18
11:48 am
alny
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Low
Report
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
11/14
04:30 am
alny
How Recent Developments Are Shaping the Alnylam Pharmaceuticals Investment Story [Yahoo! Finance]
Low
Report
How Recent Developments Are Shaping the Alnylam Pharmaceuticals Investment Story [Yahoo! Finance]
11/13
09:36 am
alny
Alnylam Pharmaceuticals (ALNY) Surged on Strong Growth and Optimistic Revenue Outlook [Yahoo! Finance]
Low
Report
Alnylam Pharmaceuticals (ALNY) Surged on Strong Growth and Optimistic Revenue Outlook [Yahoo! Finance]
11/12
02:54 pm
alny
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money [Yahoo! Finance]
Low
Report
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money [Yahoo! Finance]
11/11
09:44 am
alny
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Wells Fargo & Company from $395.00 to $479.00. They now have an "equal weight" rating on the stock.
Low
Report
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Wells Fargo & Company from $395.00 to $479.00. They now have an "equal weight" rating on the stock.
11/10
12:42 pm
alny
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Low
Report
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/10
01:16 am
alny
Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by analysts at
Wall S
Low
Report
Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by analysts at
Wall S
11/8
07:05 pm
alny
A Closer Look at Alnylam Pharmaceuticals (ALNY) Valuation Following Improved Earnings and Raised Revenue Guidance [Yahoo! Finance]
Low
Report
A Closer Look at Alnylam Pharmaceuticals (ALNY) Valuation Following Improved Earnings and Raised Revenue Guidance [Yahoo! Finance]
11/8
04:57 pm
alny
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
Low
Report
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
11/5
08:44 am
alny
Antisense and RNAi Therapeutics Market to Reach USD 18.48 Billion by 2032, Growth Driven by Rising Prevalence of Genetic Diseases and Advances in Precision Medicine — SNS Insider [Yahoo! Finance]
Neutral
Report
Antisense and RNAi Therapeutics Market to Reach USD 18.48 Billion by 2032, Growth Driven by Rising Prevalence of Genetic Diseases and Advances in Precision Medicine — SNS Insider [Yahoo! Finance]
11/4
08:43 am
alny
Alnylam Pharmaceuticals (NASDAQ:ALNY) was given a new $570.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
Low
Report
Alnylam Pharmaceuticals (NASDAQ:ALNY) was given a new $570.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
11/4
08:00 am
alny
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Low
Report
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
11/2
01:15 am
alny
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at
Wall
Medium
Report
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at
Wall
11/1
04:59 am
alny
How Alnylam's Raised 2025 Revenue Outlook and AMVUTTRA Uptake Will Impact ALNY Investors [Yahoo! Finance]
Medium
Report
How Alnylam's Raised 2025 Revenue Outlook and AMVUTTRA Uptake Will Impact ALNY Investors [Yahoo! Finance]
10/31
04:02 pm
alny
Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak [Seeking Alpha]
Medium
Report
Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak [Seeking Alpha]
10/31
12:25 pm
alny
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $489.00 price target on the stock, up previously from $449.00.
Low
Report
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $489.00 price target on the stock, up previously from $449.00.
10/31
11:35 am
alny
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Barclays PLC from $460.00 to $527.00. They now have an "overweight" rating on the stock.
Low
Report
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Barclays PLC from $460.00 to $527.00. They now have an "overweight" rating on the stock.
10/31
07:19 am
alny
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..